Gam joined Cytopharma as CEO in 2019 and today leads 100 employees. Cytopharma specialized in oncologic sterile injectables. In 2024, the company’s revenue grew 42% versus 2023, and the firm renewed its EU GMP certification. In 2024, She advanced initiatives including a joint venture for an oncologic plant in Saudi Arabia and registration of the first oncologic biosimilar in Tunisia and CIS. Gam is President of Tunisia Health Alliance and an Independent Board Member at Julphar.